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ABSTRACT
OBJECTIVE: To describe the evolution of serological markers among HIV and hepatitis B coinfected 
patients, with emphasis on evaluating the reactivation or seroreversion of these markers.
METHODS: The study population consisted of patients met in an AIDS Outpatient Clinic in São 
Paulo State, Brazil. We included in the analysis all HIV-infected and who underwent at least two 
positive hepatitis B surface antigen serological testing during clinical follow up, with tests taken 
six months apart. Patients were tested with commercial kits available for hepatitis B serological 
markers by microparticle enzyme immunoassay. Clinical variables were collected: age, sex, CD4+ 
T-cell count, HIV viral load, alanine aminotransferase level, exposure to antiretroviral drugs 
including lamivudine and/or tenofovir.
RESULTS: Among 2,242 HIV positive patients, we identified 105 (4.7%) patients with chronic 
hepatitis B. Follow up time for these patients varied from six months to 20.5 years. All patients 
underwent antiretroviral therapy during follow-up. Among patients with chronic hepatitis B, 
58% were hepatitis B “e” antigen positive at the first assessment. Clearance of hepatitis B surface 
antigen occurred in 15% (16/105) of patients with chronic hepatitis B, and 50% (8/16) of these 
patients presented subsequent reactivation or seroreversion of hepatitis B surface antigen. Among 
hepatitis B “e” antigen positive patients, 57% (35/61) presented clearance of this serologic marker. 
During clinical follow up, 28.5% (10/35) of those who initially cleared hepatitis B “e” antigen 
presented seroreversion or reactivation of this marker. 
CONCLUSIONS: Among HIV coinfected patients under antiretroviral therapy, changes of HBV 
serological markers were frequently observed. These results suggest that frequent monitoring of 
these serum markers should be recommended.
DESCRIPTORS: HIV infection, Hepatitis B, Chronic, immunology. Coinfection. Biomarkers. 
Seroepidemiologic Studies. 
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INTRODUCTION
Among the estimated 40 million people living with human immunodeficiency virus (HIV) 
worldwide, it is believed that approximately four million (10%) are coinfected with hepatitis 
B virus (HBV)1. This is mainly because both viruses share the same routes of transmission.
The presence of HIV seems to alter the natural evolution of hepatitis B infection. It is 
believed that the presence of HIV could decrease the chance of HBV viral clearance after an 
acute infection and increase the risk for HBV chronic infection. Individuals with HIV-HBV 
coinfection have higher HBV DNA levels, rapid liver disease progression, and increased liver 
disease-related mortality, when compared to HBV monoinfected patients2.
Immunosuppression associated with HIV infection or interruption of anti-HBV treatment 
may lead to HBV reactivation, even in individuals with evidence of prior positive antibody to 
the hepatitis B surface antigen (anti-HBs)3,4. Furthermore, immunosuppression associated 
with HIV infection may be related to the inability to produce antibodies in the presence 
of an HBV infection. Therefore, atypical serological patterns have been described in this 
population. The presence of HBV variants with specific mutations has also been frequently 
described in the same population, and has been associated with some atypical serological 
patterns found in coinfected patients5.
Evolution of hepatitis B serological markers among HIV coinfected patients has been evaluated 
by some authors, and these studies reveal great variation of these markers during clinical follow 
up6,7. In Brazil, however, data regarding this aspect of HBV infection in this population is scarce.
This study aimed to describe the evolution of hepatitis B surface antigen (HBsAg) and 
hepatitis B “e” antigen (HBeAg) among HIV coinfected patients, with emphasis on the 
reactivation or seroreversion of these markers in this group of patients.
METHODS
The enrolled patients were selected from those regularly followed up at an HIV Outpatient Clinic 
in São Paulo, Brazil, between May 2006 and July 2011. All HIV-infected patients with serum 
hepatitis B surface antigen HBsAg were identified. HBsAg-positive patients who underwent at 
least two repeated HBV serological testing, during clinical follow up, with tests taken six months 
apart, were included in the analysis. The study was conducted from June 2011 to July 2012.
The search for information about HBsAg-reactive patients started with an electronic and 
written database query. The serological profile analysis relative to hepatitis B in all patients 
with regular treatments during the determined time frame (between May 2006 and July 2011) 
identified HBsAg positive patients. We included all serological tests found for each patient, 
containing serological markers of HBV infection.
Medical records were reviewed retrospectively to ascertain demographic and clinical 
characteristics and laboratory findings during the six months preceding the serological 
test of interest (we considered the data sample in which serological reactivation of HBsAg 
and/or HBeAg markers was first detected).
The following clinical and demographic variables were considered for analysis: sex, age, HIV or 
HBV risk factors, treatment adherence; CD4+ T-cell count; HIV viral load, alanine aminotransferase 
(ALT) level; use and duration of exposure to antiretroviral drugs (ARV); use and duration of use of 
HBV-active drugs (lamivudine, tenofovir, entecavir, or interferon). Epidemiological, clinical, and 
laboratory features were described based on the date of serological test of interest.
For each patient, we calculated the mean ALT level and CD4 count measurement for all 
measurements performed six months prior to each HBV serological test. HIV viral load was 
considered detectable when present in any sample collected during the six months before 
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the serological test of interest. The absolute values of HIV viral load will not be described, 
since the long period of follow-up did not allow the analysis using a single method.
For the purpose of this study, we considered HBsAg or HBeAg seroclearance when HBsAg 
or HBeAg, respectively, became non-reagent after being reagent, during clinical follow up.
HBsAg or HBeAg seroreversion was considered whenever these markers were detected 
reagent after being previously detected as non-reagent (with no appearance of anti-HBs or 
anti-HBe, respectively) during clinical follow up. 
HBsAg or HBeAg reactivation were considered whenever these markers were detected 
reagent after been previously detected as non-reagent (with appearance of anti-HBs or 
anti-HBe, respectively) during clinical follow-up. Follow up time was considered as the period 
of time between the first and last serologic sample containing HBsAg or HBeAg markers.
HIV results were obtained using two commercial enzyme immunosorbent assays (Organon 
Technika, Tournault, Belgium and Embrabio, São Paulo, Brazil) and confirmed using GS-HIV-1 
Western Blot (Bio-Rad, Hercules, CA). HIV RNA was quantified using the Versant HIV-1 RNA 
3.0 bDNA assay (Siemens Healthcare, Erlangen, Germany) and Nucleic Acid Sequence-Based-
Amplification (NASBA-NUCLISENS). CD4 T-lymphocyte counts were determined using the 
BD Multitest/Trucount (BD Biosciences, San Jose, CA).
A microparticle enzyme immunoassay (MEIA, AxSYM, Abbott Laboratories, Abbott Park, 
IL) was used to detect serological markers (HBsAg, anti-Hepatitis B core total antibodies, 
anti-HBs, HBeAg, and anti-HBe) at the Central Laboratory of the Hospital das Clínicas, São 
Paulo, Southeastern Brazil.
This project was approved by the Research Ethics Committee of the Department of Infectious 
and Parasitic Diseases of the Faculdade de Medicina da Universidade de São Paulo (CAPPesq 
Protocol 0197/11, from November 5, 2011). It was exempted of the need for an informed 
consent form for patients. Secrecy and confidentiality were guaranteed in this study.
The analyses were performed from a database entered into Microsoft Excel. A descriptive 
analysis of the study variables was carried out.
Due to the small number of patients included in the study, we were not able to compare the 
possible associations between the different patterns of serological evolution observed and 
the clinical or epidemiological variables described.
RESULTS
Initially, 2,242 patients were enrolled in the AIDS Outpatient Clinic with confirmed HIV 
infection and serological markers for hepatitis B. Of those, 105 (4.7%) were patients with 
chronic hepatitis B.
The clinical and epidemiological features of the 105 included HBsAg-positive patients are 
shown in Table 1.
Most patients were male (97%), with the main risk factor for exposure to both infections 
(HIV and HBV) being risky sexual behavior (including same-sex relations). All patients 
underwent antiretroviral therapy during the monitoring phase. A total of 44% (46/105) of 
patients had a history of one or more previous AIDS defining illness. CD4+ T-cell counts 
varied from 10 to 1,536 cells/mm3, with the average count being 449.2 cells/mm3 (standard 
deviation [SD] = 211.5 cells/mm3). A total of 101 (96%) and 78 (74%) patients used lamivudine 
or tenofovir, respectively, in their therapeutic regimen during follow up.
Follow up time for these 105 patients varied from six months to 20.5 years.
The number of serological testing for each patient varied from two to 18 along this period.
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Among those with HBsAg positive, 58% (61/105) were also HBeAg positive.
Clearance of HBsAg occurred in 15% (16/105) of patients with chronic hepatitis B (1.7 cases 
per 100 person-years), and 50% of them (8/16) presented subsequent seroreversion or 
reactivation of HBsAg during clinical follow up. Two patients (25%) presented anti-HBs 
before HBsAg reactivation.
Follow up time for patients who underwent HBsAg reappearance varied from 1,775 to 6,051 
days (4.9 years to 16.8 years).
Clinical characteristics of patients who presented HBsAg reactivation are summarized in Table 2.
Among HBeAg positive patients at the first serologic test, 57% (35/61) underwent clearance 
of this serologic marker (5.8 cases per 100 person-years). During clinical follow up, 28.5% 
Table 1. Epidemiological, clinical, and laboratory features of 105 HBsAg-reactive patients coinfected 
with HIV.
Demographic and epidemiological variables n %
Men 102 97.1
Mean age (years) 50.4 SD = 8.2
Background MSM 54 51.4
Background IDU 6 5.7
Clinical variables
Previous ARV use 105 100
Previous lamivudine use 101 96.0
Previous tenofovir use (TDF) 78 74.0
Previous LAM, TDF, ENT, or IFN use 101 96.0
Previous entecavir use (ENT) 4 3.8
Previous interferon use (IFN) 5 4.7
History of AIDS-defining illness 46 43.8
Laboratory variables
HBeAg reactivity 61 58.0
Mean CD4+ T-cells 4,492
Variation: 10-1,536
SD = 211.5 cells/mm3
Elevation ALT >1.5 × ULN† 61 58.0
MSM: men who have sex with men; IDU: injection drug use; ARV: antiretroviral drug; TDF: Tenofovir; LAM: 
Lamivudine; ENT: Entecavir; IFN: Interferon; ALT: alanine aminotransferase; ULN: upper limit of normality
Table 2. Clinical characteristics of patients who underwent HBsAg reappearance.
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HIV viremia at 
seroreversion 
detection
Exposure to  
anti-hepatitis 









ALT level at 
seroreversion 
detection
1 Non reagent 380 No Yes No No NA 1.5 to 2.5 ULN
2 Non reagent 462 No No Yes No NA < 1.5 ULN
3 Reagent 448 No Yes Yes LAM No 2.5 to 3.5 ULN
4 Reagent 618 No Yes Yes No NA 3.5 to 5 ULN
5 Non reagent 546 No Yes No LAM No < 1.5 ULN
6 Reagent 422 No Yes No No NA < 1.5 ULN
7 Non reagent 478 Kaposi Sarcoma Yes Yes LAM No < 1.5 ULN
8 Non reagent 365 No Yes No LAM+TDF No < 1.5 ULN
HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B “e” antigen; ARV: antiretroviral drug; LAM: Lamivudine; TDF: Tenofovir; NA: not applicable; ALT: 
alanine aminotransferase; ULN: upper limit of normality
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(10/35) of those who initially cleared HBeAg presented HBeAg reactivation or seroreversion. 
Five patients (50%) presented anti-HBe before HBeAg reactivation.
Follow up time for patients who underwent HBeAg reappearance varied from 1,296 to 5,087 
days (3.6 years to 14.1years).
Clinical characteristics of these patients are described in Table 3. All patients were male, 
with average age of 56 years (SD = 11). The average CD4+ T-cell count was 588 cells/mm3.
DISCUSSION
In this study, changes of HBV serological markers were frequent among HIV-HBV coinfected 
patients during their clinical follow up. We identified high initial HBsAg and HBeAg clearance 
rates, at 15.2% and 57%, respectively. Then, we observed HBsAg and HBeAg reappearance in 
50% and 28.6% of patients, respectively, throughout their clinical monitoring.
HBsAg and HBeAg serological clearance has been analyzed and extensively described among 
monoinfected HBV patients. This is a phenomenon observed in the natural course of this infection 
and depends on different factors. During hepatitis B treatment, the type of drug and period of 
exposure to a specific regimen are associated with different clearance rates observed throughout 
clinical monitoring for both antigens; however, the clearance rates increase with monitoring time7,8.
Few studies have evaluated this issue among HIV coinfected patients, yet our study confirms 
what was previously evaluated by some authors. After five years of monitoring, Sheng et 
al.9 found an HBsAg clearance rate of 14.4% in HIV coinfected patients. On the other hand, 
Nunez et al.10 and Maylin et al.11 observed a loss of HBsAg and HBeAg, varying from 2.8 to 
13% and 17.7 to 27.7%, respectively.
Overall, the adequate use of ARV may have an important impact on the natural course of 
HIV infection, restoring specific adaptive and nonspecific innate immune responses2,12. It is 
important to emphasize that this impact is independent of the use of drugs with anti-HBV 
action in this medication regimen. The use of lamivudine, emtricitabine, or tenofovir 
enhances this impact, as HBV infection replication decreases, thus contributing concurrently 
and significantly to the patient’s overall immune response restoration. Coinfected patients 
with no treatment exhibit a lower average CD4+ count and greater HIV viral loads when 
compared to HBV monoinfected individuals13,14.
Table 3. Clinical characteristics of patients who underwent HBeAg reappearance.
ID

















B drugs before 
seroreversion 
detection






ALT level at 
seroreversion 
detection
10 reagent 682 No No Yes No NA < 1.5 ULN
17 reagent 871 No Yes Yes LAM+TDF Yes 1.5 to 2.5 ULN
18 reagent 613 No Yes No LAM No < 1.5 ULN
19 reagent 494 No Yes Yes LAM+TDF Yes < 1.5 ULN
20 reagent 431 No Yes No LAM No 1.5 to 2.5 ULN
21 reagent 292 Lung Tb No No No NA > 5 ULN
22 reagent 498 No Yes No LAM No 1.5 to 3.5 ULN
23 reagent 739 No Yes No LAM+TDF No 1.5 to 2.5 ULN
24 reagent 858 No Yes No LAM+TDF No < 1.5 ULN
25 reagent 402 No No Yes No NA < 1.5 ULN
HBeAg: hepatitis B “e” antigen; Tb: tuberculosis; ARV: antiretroviral drug; LAM: Lamivudine; TDF: Tenofovir; NA: non aplicable; ALT: alanine 
aminotransferase; ULN: upper limit of normality
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Therefore, it is possible to suppose that the high HBsAg and HBeAg clearance rates observed 
among coinfected patients may be partly due not only to the antiviral action of anti-HBV 
drugs used in most patients, but also to the immunomodulatory action of the medication 
therapy as a whole. In accordance to this, HBsAg seroconversion to anti-HB has been 
frequently described after introduction of antiretroviral treatment in this population15.
High rates of HBsAg and HBeAg reappearance were observed in our study. Matthews et al.16 
identified HBsAg and HBeAg reactivation, respectively, in one and two patients, among the 
47 monitored over 42 months. Di Martino et al.17 observed HBeAg reversion in five patients, 
among the 14 monitored over 24 months, who were subjected to interferon therapy for 
chronic hepatitis B treatment.
It is possible that different causes might be associated with the frequent serological variations 
observed in our study. First, to the best of our knowledge, until now, no other research group 
has monitored patients’ HBV serological markers, among HIV infected patients using ARV, 
for such a long time. Second, aspects related to the sensitivity of the serological methods 
involved could also be associated with some of the serological alterations observed among 
our patients. Small titer oscillations of those markers above or below the detection limit could 
eventually have generated some of the alterations observed in the patients included in our 
study; as such, the HBsAg or HBeAg reemergence may not have represented real reactivations, 
but instead titer oscillations of these markers. It is also possible that intercurrent plasmatic 
factors associated with other concomitant infections in this group of patients could have, 
in some way, interfered with some of the results observed. In this sense, Rabenau et al.18, 
using the AxSYMTM method for HBsAg detection, described significant statistical differences 
between samples of anti-HB-positive and anti-HB-negative plasma saturated with HBsAg.
Third, it is possible to suppose that some of the included patients could have selected 
mutations in the surface antigen genes or in the precore/core genes. The presence of these 
mutations could have been associated with the absence of HBsAg or HBeAg in some of the 
included patients. In this regard, a recent study evaluated alterations in the HBV genome 
among coinfected patients over time, and identified important evolutionary alterations in the 
patients’ viral genome19. Numerous amino acid variations were found; however, the mutants 
specifically selected for defects in diagnostic tests were not observed in that particular study.
Also, all patients included in this study were under ARV. Among them, 96% had used 
lamivudine and 74% had used tenofovir, according to medical records. Therefore, nearly 
26% of patients were submitted to lamivudine monotherapy for some time. Lamivudine 
monotherapy is frequently associated with the selection of mutants in the polymerase 
region20. In this case, mutations in the S gene region could eventually have been selected 
among the analyzed patients21. Unfortunately, HBV DNA quantification or the identification 
of mutations in the serum of these patients was not available for analyses.
The presence of the virus genotype G among the patients could also have contributed to 
the HBeAg variations observed. Genotype G has been associated with the presence of two 
codons responsible for the translation termination in the HBV precore region, which seem 
to inhibit the synthesis of HBeAg22. It is interesting to note that the presence of genotype G 
was previously described by other authors in a few patients from the same study population23. 
The presence of the HBV genotypes C and F could also have been associated with a greater 
chance of HBeAg seroreversion in that population24.
It is important to mention, however, that this study has some limitations. It was a retrospective 
analysis of the medical records, which makes it impossible to precisely evaluate some aspects 
regarding patients’ general adherence to treatment. Similarly, the lack of prospective and 
systematically collected ALT data may have limited our observation of ALT alterations 
preceding the episodes of reemergence of HBsAg or HBeAg. However, we emphasize that 
although there was no acute evidence of ALT elevations in the group of patients analyzed, 
the impact of HBsAg and HBeAg marker reactivation or seroreversion, in increased disease 
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severity, should not be discarded. Studies on HBV monoinfection have clearly associated HBsAg 
reactivation and HBeAg seroreversion with a worse prognosis of liver disease25. Also, the small 
sample of patients included did not allow us to analyze possible associations between the 
evolution of serological markers and the clinical and laboratory variables described.
In conclusion, changes of HBV serological markers were frequently observed in our study. 
High HBsAg and HBeAg clearance rates, as well as reemergence of these markers, were also 
observed in this population. Our data suggest that periodic measurements of HBV serological 
markers should be recommended.
REFERENCES 
1. Alter M. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44 Suppl 1:S6-9. 
https://doi.org/10.1016/j.jhep.2005.11.004
2. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected 
patients. J Hepatol. 2006;44 Suppl 1:S65-70. https://doi.org/10.1016/j.jhep.2005.11.015
3. Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, et al. Reactivation 
of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active 
antiretroviral therapy. Clin Infect Dis. 2001;32(1):144-8. https://doi.org/10.1086/317535
4. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Impact of hepatitis B 
virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. 
Clin Infect Dis. 2009;49(8):1268-73. https://doi.org/10.1086/605675
5. Avelino-Silva VI, Miraglia JL, Gomes-Gouvêa MS, Pinho JR, Mendes-Corrêa MC. Absence of 
anti-hepatitis B virus (HBV) core in HIV/HBV coinfection with advanced immunosuppression. 
HIV Med. 2013;14(7):453-4. https://doi.org/10.1111/hiv.12040
6. Piroth L, Binquet C, Vergne M, Minello A, Livry C, Bour JB, et al. The evolution of 
hepatitis B virus serological patterns and the clinical relevance of isolated antibodies 
to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36(5):681-6. 
https://doi.org/10.1016/S0168-8278(02)00019-3
7. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg 
positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. 
J Hepatol. 2007;46(1):45-52. https://doi.org/10.1016/j.jhep.2006.08.021
8. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon 
Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 
2005;352(26):2682-95. https://doi.org/10.1056/NEJMoa043470
9. Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, et al. Evolution of hepatitis B 
serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin 
Infect Dis. 2007;45(9):1221-9. https://doi.org/10.1086/522173
10. Núñez M, Ramos B, Díaz-Pollán B, Camino N, Martín-Carbonero L, Barreiro P, et al. 
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving 
anti-VHB active antiretroviral therapy. AIDS Res Hum Retroviruses. 2006;22(9):842-8. 
https://doi.org/10.1089/aid.2006.22.842
11. Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, et al. Kinetics of 
hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in 
antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS. 2012;26(8):939-49. 
https://doi.org/10.1097/QAD.0b013e328352224d
12. Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, et al. 
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based 
HAART in HBV-HIV-coinfected patients. J Viral Hepat. 2012;19(11):801-10. 
https://doi.org/10.1111/j.1365-2893.2012.01601.x
13. Gilson RJC, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, et al. Interactions between 
HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 
1997;11(5):597-606. https://doi.org/10.1097/00002030-199705000-00007
14. Wang H, Li Y, Zhang C, Han Y, Zhang X, Zhu T, et al. Immunological and virological responses 
to combined antiretroviral therapy in HIV/hepatitis B virus-coinfected patients from a multicenter 
cohort. AIDS. 2012;26(14):1755-63. https://doi.org/10.1097/QAD.0b013e328355ced2
8Evolution of hepatitis B serological markers Toscano ALCC and Mendes-Corrêa MC
https://doi.org/10.1590/S1518-8787.2017051006693
15. Velasco M, Morán A, Téllez MJ. Resolution of chronic hepatitis B after ritonavir 
treatment in an HIV-infected patient. N Engl J Med. 1999;340(22):1765-6. 
https://doi.org/10.1056/NEJM199906033402215
16. Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, Bowden S, et al. 
Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation 
of HAART in HIV-HBV coinfected individuals. PLoS One. 2013;8(4):e61297. 
https://doi.org/10.1371/journal.pone.0061297
17. Di Martino V, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, et al. Influence of HIV 
infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. 
Gastroenterology. 2002;123(6):1812-22. https://doi.org/10.1053/gast.2002.37061
18. Rabenau H, Schütz R, Berger A, Doerr HW, Weber B. How accurate is serologic testing 
of plasma pools for hepatitis B virus surface antigen, anti-human immunodeficiency 
virus 1 and 2, and anti-hepatitis C virus? Infusionsther Transfusionsmed. 1996;23(3):124-30. 
https://doi.org/10.1159/000223281
19. Taffon S, Genovese D, Blasi M, Pierotti P, Degli Esposti A, Catone S, et al. HBV whole-genome 
mutation profile in HIV-1/HBV coinfected patients in a long-term follow-up study. Infection. 
2014;42(4):675-87. https://doi.org/10.1007/s15010-014-0616-2
20. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term 
incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency 
virus-infected patients. Hepatology. 1999;30(5):1302-6. https://doi.org/10.1002/hep.510300525
21. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et 
al. Characteristics of drug resistant HBV in an international collaborative study of 
HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. 2006;20(6):863-70. 
https://doi.org/10.1097/01.aids.0000218550.85081.59
22. Kato H, Orito E, Gish RG, Sugauchi F, Suzuki S, Ueda R, et al. Characteristics of hepatitis B 
virus isolates of genotype G and their phylogenetic differences from the other six genotypes 
(A through F). J Virol. 2002;76(12):6131-7. https://doi.org/10.1128/JVI.76.12.6131-6137.2002
23. Silva AC, Spina AMM, Lemos MF, Oba IT, Guastini CF, Gomes-Gouvêa MS, et al. Hepatitis 
B genotype G and high frequency of lamivudine-resistance mutations among human 
immunodeficiency virus/hepatitis B virus co-infected patients in Brazil. Mem Inst Oswaldo Cruz. 
2010;105(6):770-8. https://doi.org/10.1590/S0074-02762010000600007
24. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al. Clearance 
of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. 
Gastroenterology. 2007;133(5):1452-7. https://doi.org/10.1053/j.gastro.2007.08.010
25. Lu ZH, Chen W, Ju ZC, Pei H, Yang XJ, Gu XB, et al. Pathological features and 
prognosis in chronic hepatitis B virus carriers. J Int Med Res. 2011;39(1):71-7. 
https://doi.org/10.1177/147323001103900109
Authors’ Contribution: Conception and planning of the study, data collection, data analysis and interpretation: 
ALCCT, MCMC. Preparation and writing of the manuscript: ALCCT. Critical review of the manuscript: MCMC. 
Both authors have approved the final version to be published.
Conflict of Interest: The authors declare no conflict of interest.
